Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using topical Minoxidil and Finasteride for 5 months and is questioning whether the new hair growth is genuine or just thin existing hairs. Another user suggests that comparison with before pictures is necessary to determine progress.

A 26-year-old male has been using oral finasteride for 9 months and minoxidil for 2-3 years to control hair loss but still experiences hairline recession and miniaturization. Despite additional PRP and GFC sessions, he sees no improvement and seeks advice, with suggestions to maintain consistency and consider microneedling.

Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.

The conversation discusses the storage and use of pyrilutamide for hair loss, where one user advises against keeping it in the freezer as it may crystallize the active compounds.

Excessive use of topical minoxidil led to unwanted facial changes and side effects. The user plans to switch to oral minoxidil with microneedling for hair regrowth.

PP405 is a promising hair growth stimulant but not a cure for advanced hair loss, as it may only help dormant follicles. Treatments like Minoxidil, Finasteride, and Dutasteride are discussed, with emphasis on early intervention for effectiveness.

A woman with hair loss discovered she has thyroid cancer, which was found during an MRI and confirmed with an ultrasound. She advises others with symptoms to see a doctor and shares that her cancer was detected after her dog sniffed her neck and she experienced neck pain.

The conversation discusses whether finasteride and minoxidil can help regrow hair at the corners, with one user suggesting that recovery is possible even from worse conditions.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.